KCI requests Developmental Funds in support of: 1) recruitment of new basic and translational investigators;2) innovative projects that bridge several areas of research;and 3) development of Shared Resources (Cores). KCI's Developmental Funds have been used with endorsement of the External Advisory Board and the Senior Leadership of the Cancer Center to enhance the strengths of the current scientific Programs and to increase utilization of the Shared Resources. The Developmental Funds are critical to leverage the support of key Wayne State University stakeholders and local philanthropists. KCI's use of Developmental Funds to support faculty recruitment links with our plan for scientific research investment and supports our continued efforts to grow translational research by increasing interactions among basic scientists and clinicians. The Institute will continue its successful Strategic Research Initiative Grant program and its new Joint Post-Doctoral Training program in order to stimulate projects that have a high potential to go on to program project or SPORE applications. Two new developing Cores are proposed in this application for support from Developmental Funds. The proposed Clinical Imaging Researcii Core promotes imaging in support of cancer detection and therapy and facilitates the integration of functional imaging into routine clinical practice. Finally, the proposed Translational Research Core offers services to develop biochemical, molecular, or cellular assays tailored and validated according to the specific and customized translational research question associated with clinical trials.
Developmental Funds provide support to KCI to: 1) recruit new basic and translational investigators;2) support innovative projects that bridge several areas of research;and 3) support developing Shared Resources (Cores).
|Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12|
|Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5|
|Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7|
|Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6|
|Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202|
|Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018|
|Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867|
|Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54|
|Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830|
|Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84|
Showing the most recent 10 out of 321 publications